Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04162210 · OUTCOME

Number of Participants With Shift in Urine Albumin Creatinine Ratio From Baseline to Worst Post-Baseline

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline (Day 1) and Up to approximately 263 weeks

What was measured

Urine samples were analyzed for spot urine albumin/creatinine ratio (UACR)\[milligrams/grams (mg/g)\]. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The "worst post-baseline value" is defined as the highest UACR measurement recorded for a participant after the baseline assessment and up to the end of the study observation period. The "shift" will be calculated as the difference between this worst post-baseline UACR value and the baseline UACR value (Worst Post-Baseline UACR - Baseline UACR). Each category is reported as "Baseline category, Worst post-baseline category." Ranges are inclusive and expressed as \[lower-upper\].

Analysis population: Safety Population

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Pomalidomide Plus Dexamethasone

Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Belantamab Mafodotin217
Pomalidomide Plus Dexamethasone102

Reported measurements

Baseline [< 500, < 500]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin129Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone57Not reportedNot reportedNot reportedNot reported
Worst post-baseline [< 500, (500, 2000)]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin25Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone2Not reportedNot reportedNot reportedNot reported
Worst post-baseline [< 500, > 2000]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin5Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [< 500, Missing]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin23Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone16Not reportedNot reportedNot reportedNot reported
Worst post-baseline [(500, 2000), < 500]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin2Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone1Not reportedNot reportedNot reportedNot reported
Worst post-baseline [(500, 2000), (500, 2000)]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin2Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [(500, 2000), > 2000]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin1Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [(500, 2000), Missing]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin0Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [> 2000, < 500]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin0Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [> 2000, (500, 2000)]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin0Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [> 2000, > 2000]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin1Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [> 2000, Missing]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin0Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [Missing, < 500]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin21Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone17Not reportedNot reportedNot reportedNot reported
Worst post-baseline [Missing, (500, 2000)]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin2Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [Missing, > 2000]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin1Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone0Not reportedNot reportedNot reportedNot reported
Worst post-baseline [Missing, Missing]
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Belantamab Mafodotin5Not reportedNot reportedNot reportedNot reported
Pomalidomide Plus Dexamethasone9Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        129
      2. group Id
        OG001
        value
        57
    title
    Baseline [< 500, < 500]
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        25
      2. group Id
        OG001
        value
        2
    title
    Worst post-baseline [< 500, (500, 2000)]
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        5
      2. group Id
        OG001
        value
        0
    title
    Worst post-baseline [< 500, > 2000]
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        23
      2. group Id
        OG001
        value
        16
    title
    Worst post-baseline [< 500, Missing]
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        1
    title
    Worst post-baseline [(500, 2000), < 500]
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        0
    title
    Worst post-baseline [(500, 2000), (500, 2000)]
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    Worst post-baseline [(500, 2000), > 2000]
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Worst post-baseline [(500, 2000), Missing]
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Worst post-baseline [> 2000, < 500]
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Worst post-baseline [> 2000, (500, 2000)]
  11. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
    title
    Worst post-baseline [> 2000, > 2000]
  12. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Worst post-baseline [> 2000, Missing]
denoms
  1. counts
    1. group Id
      OG000
      value
      217
    2. group Id
      OG001
      value
      102
    units
    Participants
description
Urine samples were analyzed for spot urine albumin/creatinine ratio (UACR)\[milligrams/grams (mg/g)\]. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The "worst post-baseline value" is defined as the highest UACR measurement recorded for a participant after the baseline assessment and up to the end of the study observation period. The "shift" will be calculated as the difference between this worst post-baseline UACR value and the baseline UACR value (Worst Post-Baseline UACR - Baseline UACR). Each category is reported as "Baseline category, Worst post-baseline category." Ranges are inclusive and expressed as \[lower-upper\].
groups
  1. description
    Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
    id
    OG000
    title
    Belantamab Mafodotin
  2. description
    Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
    id
    OG001
    title
    Pomalidomide Plus Dexamethasone
param Type
COUNT_OF_PARTICIPANTS
population Description
Safety Population
reporting Status
POSTED
time Frame
Baseline (Day 1) and Up to approximately 263 weeks
title
Number of Participants With Shift in Urine Albumin Creatinine Ratio From Baseline to Worst Post-Baseline
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice